# A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)

> **NCT07652736** · — · RECRUITING · sponsor: **BeOne Medicines** · enrollment: 440 (estimated)

## Conditions studied

- Advanced Non-Small Cell Lung Cancer
- Extensive-Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT07652736
- **Lead sponsor:** BeOne Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-05
- **Primary completion:** 2027-11-15
- **Final completion:** 2030-11-17
- **Target enrollment:** 440 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07652736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07652736, "A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07652736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*